Lv3
390 积分 2025-07-09 加入
95MO Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
2个月前
已关闭
95MO Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
3个月前
已关闭
Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer
3个月前
已完结
Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158
4个月前
已完结
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
4个月前
已关闭
Preoperative pembrolizumab (Pembro) with radiation therapy (RT) in patients with operable triple-negative breast cancer (TNBC)
6个月前
已关闭
Sutureless aortic valves in isolated and combined procedures: Thirteen years of experience in 784 patients
6个月前
已完结
Abstract P3-11-08: Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute
7个月前
已关闭
乳腺良性硬化性病变基础上发生的低级别腺鳞癌临床病理学分析
8个月前
已完结
Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast
8个月前
已完结
皖公网安备34019202002308
